13F Holdings
中文EN

XGN EXAGEN INC.

Services-Medical Laboratories · Nasdaq · SEC CIK 1274737 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.7%
TTM net income YoY4.6%
TTM EPS YoY18.3%
Revenue 3-yr CAGR11.9%
Net income 3-yr CAGR—

Margins

Gross margin58.7%
Operating margin-20.1%
Net margin-25.1%
FCF margin-18.0%
EBITDA margin-16.6%

Returns

ROE-113.9%
ROA-30.8%
ROIC (approx.)-167.2%
Asset turnover1.22x

Leverage & solvency

Liabilities / assets75.1%
Debt / equity1.66x
Current ratio3.46x
Interest coverage-2.90x

Cash quality & payout

Operating cash flow / net income0.66x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue1.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$66.58M$55.64M$52.55M$45.56M$48.30M
Cost of revenue$27.78M$22.53M$23.09M$24.21M$20.59M
Gross profit$38.80M$33.11M$29.46M$21.35M$27.71M
R&D expense$6.25M$5.38M$4.87M$9.88M$7.24M
SG&A expense$46.62M$41.37M$47.43M$52.02M$44.54M
Operating income-$14.07M-$13.64M-$22.84M-$46.05M-$24.07M
Interest expense$4.32M$2.23M$2.33M$2.45M$2.62M
Income tax$51,000$12,000$33,000-$282,000$175,000
Net income-$19.95M-$15.12M-$23.69M-$47.39M-$26.85M
EBITDA-$11.97M-$11.94M-$20.64M-$44.45M-$23.17M
EPS (basic)-0.93-0.83-1.34-2.77-1.68
EPS (diluted)-0.93-0.83-1.34-2.77-1.68
Weighted avg. shares (diluted)21.56M18.20M17.68M17.08M15.97M
Balance sheet
Cash & equivalents$32.22M$22.24M$36.69M$62.59M$99.54M
Receivables$10.86M$7.83M$6.60M$6.10M$9.70M
Current assets$48.89M$36.45M$47.84M$72.61M$112.73M
PP&E, net$6.94M$5.28M$5.20M$8.20M$4.77M
Goodwill———$0$5.51M
Total assets$58.02M$44.69M$56.94M$86.22M$123.44M
Current liabilities$14.16M$13.51M$11.90M$9.62M$9.32M
Short-term debt$643,000$423,000$264,000$190,000$0
Long-term debt$22.26M$19.82M$19.23M$28.78M$27.48M
Total debt$22.91M$20.25M$19.50M$28.97M$27.48M
Total liabilities$40.57M$35.15M$34.25M$43.76M$38.51M
Shareholders' equity$17.45M$9.54M$22.69M$42.46M$84.94M
Net debt-$9.31M-$1.99M-$17.20M-$33.62M-$72.06M
Shares outstanding22.91M17.64M17.05M16.55M16.16M
Cash flow statement
Operating cash flow-$13.62M-$13.28M-$14.46M-$32.14M-$20.27M
Capital expenditure$641,000$515,000$828,000$4.32M$2.37M
Free cash flow-$14.27M-$13.79M-$15.29M-$36.46M-$22.64M
Investing cash flow-$626,000-$515,000-$804,000-$4.32M-$2.42M
Financing cash flow$24.43M-$663,000-$10.63M-$489,000$64.68M
Depreciation & amortization$2.10M$1.70M$2.20M$1.60M$900,000
Stock-based compensation$2.16M$1.76M$3.62M$4.70M$4.73M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.